Top

Osteoporosis International

Published in:

01-10-2009 | Original Article

Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

Authors: J. D. Adachi, C. C. Kennedy, A. Papaioannou, G. Ioannidis, W. D. Leslie, V. Walker

Published in: Osteoporosis International | Issue 10/2009

Abstract

Summary

Using a Markov state-transition model, we estimated fractures averted with risedronate using two different types of clinical efficacy data. Summary data, as opposed to individual patient data (IPD), underestimated the number of fractures averted when applied in a specified high risk population. The choice of clinical efficacy data is an important consideration in health economic models evaluating osteoporosis therapies.

Introduction

This paper contrasts fracture reduction estimates for risedronate utilizing efficacy data from two approaches to meta-analysis: summary data versus individual patient data. We also examined differences in fracture reduction explained by varied cohort selection, especially the inclusion of low- versus high-risk populations.

Methods

Using a Markov state-transition model, we compared fractures averted over 3 years in a hypothetical cohort by inputting fracture risk reduction estimates (risedronate versus placebo) from two data sources (summary data versus IPD). The cohort consisted of 100,000 Canadian women, age ≥65 years with osteoporosis (WHO criteria T-score ≤ -2.5) and prevalent morphometric vertebral fracture.

Results

Non-vertebral fractures averted with risedronate were: 3,571 and 6,584 per 100,000 women for summary data and IPD, respectively. For vertebral fractures, the numbers were 8,552 and 10,127. When IPD versus summary data was used, an additional 3,013 more non-vertebral fractures and 1,575 vertebral fractures were averted.

Discussion

Relative risk estimates from IPD analyses were the best choice for modelling fracture outcomes when applied in a specified high-risk population. In addition to superior statistical methodology, they utilized RCT cohorts that are more representative of higher risk patients requiring treatment (osteoporotic women ≥65 years with a prevalent vertebral fracture).

Sawka AM, Thabane L, Papaioannou A, Gafni A, Ioannidis G, Hanley DA, Papadimitropoulos E, Pickard L, Adachi JD (2004) The number of Canadian men and women needed to be screened to detect a case of osteoporosis: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). J Bone Miner Res 19:S368

Doherty DA, Sanders KM, Kotowicz MA, Prince RL (2001) Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 12:16–23PubMedCrossRef

Cummings SR, Black DM, Rubin SM (1989) Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445–2448PubMedCrossRef

Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992) Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005–1010PubMedCrossRef

Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12:271–278PubMedCrossRef

Brown JP, Josse RG (2002) clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–34PubMed

Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G (2005) Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127:335–371PubMedCrossRef

Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523PubMedCrossRef

Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516PubMedCrossRef

10.

Boonen S, Laan RF, Barton IP, Watts NB (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291–1298PubMedCrossRef

11.

Delmas PD Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599–604CrossRef

12.

Adachi JD, Rizzoli R, Boonen S Li Z, Meredith MP, Chesnut CH III (2005) Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin Exp Res 17:150–156PubMed

13.

Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135PubMedCrossRef

14.

Stewart LA Tierney JF (2002) To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 25:76–97CrossRef

15.

Smith CT, Williamson PR, Marson AG (2005) An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes. J Eval Clin Pract 11:468–478PubMedCrossRef

16.

Lambert PC, Sutton AJ, Abrams KR, Jones DR (2002) A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 55:86–94PubMedCrossRef

17.

Chalmers I (1993) The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci 703:156–163PubMedCrossRef

18.

Grima DT, Burge RT, Becker DL, Tosteson AN (2002) Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 27:448–455

19.

Tosteson AN, Jonsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857PubMedCrossRef

20.

Papaioannou A, Wiktorowicz ME, Adachi JD, Goeree R, Papadimitropoulos E, Bedard M, Brazil K, Parkinson W, Weaver B (2000) Mortality, independence in living, and re-fracture, one year following hip fracture in Canadians. J Obstet Gynaecol Can 22:591–597

21.

Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRef

22.

Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995PubMedCrossRef

23.

Papadimitropoulos EA, Coyte PC, Josse RG, Greenwood CE (1997) Current and projected rates of hip fracture in Canada. CMAJ 157:1357–1363PubMed

24.

Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL (1993) Prevalence and incidence of vertebral deformities. Osteoporos Int 3:113–119PubMedCrossRef

25.

Melton LJ III, Crowson CS, O'Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29–37PubMedCrossRef

26.

Black DM, Palermo L, Grima DT (2006) Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health 9:54–58PubMedCrossRef

27.

World Health Organization (2002) Estimates of child and adult mortality and life expectancy at birth by country. WHO, Geneva

28.

Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307:1248–1250PubMedCrossRef

29.

Cranney A, Tugwell P, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 23:496–507PubMedCrossRef

30.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRef

31.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedCrossRef

32.

McClung MR, Bensen WG, Bolognese M et al (1998) Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass. Osteoporos Int 8:111

33.

Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85:1895–1900PubMedCrossRef

34.

Hooper M, Ebeling P, Roberts A et al (1999) Risedronate prevents bone loss in early postmenopausal women. Calcif Tissue Int 64:S69CrossRef

35.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRef

36.

Teramukai S, Matsuyama Y, Mizuno S, Sakamoto J (2004) Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Jpn J Clin Oncol 34:717–721PubMedCrossRef

37.

Shih W (2002) Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 3:4PubMedCrossRef

38.

Altman DG, Bland JM (1998) Time to event (survival) data. BMJ 317:468–469PubMed

39.

Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick D (2000) Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract 6:205–214PubMedCrossRef

40.

Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:330–337PubMedCrossRef

41.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane.Database.Syst.Rev. CD004523

42.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7:488–495PubMedCrossRef

43.

Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. (1998) Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396–402PubMedCrossRef

44.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef

Title: Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?
Authors: J. D. Adachi
C. C. Kennedy
A. Papaioannou
G. Ioannidis
W. D. Leslie
V. Walker
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0870-9

At a glance: The STEP trials

Springer Medicine

Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

Abstract

Summary

Introduction

Methods

Results

Discussion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 10/2009

Determinants of 25-hydroxyvitamin D levels in African-American and Caucasian male veterans

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

Effect of impact exercise on bone metabolism

Osteoporosis in China

Use of anti-depressants and the risk of fracture of the hip or femur

Combining bone resorption markers and heel quantitative ultrasound to discriminate between fracture cases and controls